Acid-suppressing therapies and subsite-specific risk of stomach cancer

British Journal of Cancer

Volumn 116, Issue 9, 2017, Pages 1234-1238

  Wennerström, E Christina M ^a   Simonsen, Jacob ^a   Camargo, M Constanza ^b   Rabkin, Charles S ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; ACID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DANISH CITIZEN; FEMALE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONCOLOGICAL PARAMETERS; PRESCRIPTION; PRIORITY JOURNAL; STOMACH CANCER; CHEMICALLY INDUCED; COMPLICATION; DENMARK; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STOMACH; STOMACH NEOPLASMS;

ACIDS; DENMARK; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RISK FACTORS; STOMACH; STOMACH NEOPLASMS;

EID: 85016406032     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.84     Document Type: Article

References (12)

1. Ahn JS, Eom CS, Jeon CY, Park SM (2013) Acid suppressive drugs and gastric cancer: A meta-Analysis of observational studies. World J Gastroenterol 19(16): 2560-2568.
2. Camargo MC, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, Eheman CR, Rabkin CS (2011) Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut 60(12): 1644-1649.
3. Garcia Rodriguez LA, Lagergren J, Lindblad M (2006) Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: A nested case control study in the UK. Gut 55(11): 1538-1544.
4. Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39(7 Suppl): 42-45.
5. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D (2005) Gastric carcinoids: A temporal increase with proton pump introduction. Surg Endosc 19(12): 1610-1612.
6. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39(7 Suppl): 30-33.
7. Malfertheiner P, Megraud F, OMorain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM (2017) Management of Helicobacter pylori infection-The Maastricht V/Florence Consensus Report. Gut 66(1): 6-30.
8. Pottegard A, Broe A, Hallas J, de Muckadell OB, Lassen AT, Lodrup AB (2016) Use of proton-pump inhibitors among adults: A Danish nationwide drug utilization study. Therap Adv Gastroenterol 9(5): 671-678.
9. Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sorensen HT, Olsen JH, Friis S (2009) Proton pump inhibitors and risk of gastric cancer: A population-based cohort study. Br J Cancer 100(9): 1503-1507.
10. Tindberg Y, Bengtsson C, Bergstrom M, Granstrom M (2001) The accuracy of serologic diagnosis of Helicobacter pylori infection in school-Aged children of mixed ethnicity. Helicobacter 6(1): 24-30.
11. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2): 87-108.
12. Wildner-Christensen M, Touborg LA, Lindebjerg J, Schaffalitzky de Muckadell OB (2002) Diagnosis of Helicobacter pylori in bleeding peptic ulcer patients, evaluation of urea-based tests. Digestion 66(1): 9-13.